Randomized, double-blind, placebo-controlled, dose-titration, phase III study assessing the efficacy and tolerability of lanthanum carbonate: a new phosphate binder for the … MS Joy, WF Finn, LAM-302 Study Group American journal of kidney diseases 42 (1), 96-107, 2003 | 278 | 2003 |
Effect of ACE inhibitors in diabetic and nondiabetic chronic renal disease: a systematic overview of randomized placebo-controlled trials AV Kshirsagar, MS Joy, SL Hogan, RJ Falk, RE Colindres American journal of kidney diseases 35 (4), 695-707, 2000 | 268 | 2000 |
Cutaneous and systemic manifestations of drug-induced vasculitis SM Holder, MS Joy, RJ Falk Annals of Pharmacotherapy 36 (1), 130-147, 2002 | 238 | 2002 |
Long-term glycemic control measurements in diabetic patients receiving hemodialysis MS Joy, WT Cefalu, SL Hogan, PH Nachman American journal of kidney diseases 39 (2), 297-307, 2002 | 196 | 2002 |
Outcomes of secondary hyperparathyroidism in chronic kidney disease and the direct costs of treatment MS Joy, PC Karagiannis, FW Peyerl Journal of Managed Care Pharmacy 13 (5), 397-411, 2007 | 195 | 2007 |
A pilot study using mycophenolate mofetil in relapsing or resistant ANCA small vessel vasculitis MS Joy, SL Hogan, JC Jennette, RJ Falk, PH Nachman Nephrology Dialysis Transplantation 20 (12), 2725-2732, 2005 | 165 | 2005 |
Efficacy and safety of lanthanum carbonate for reduction of serum phosphorus in patients with chronic renal failure receiving hemodialysis. WF Finn, MS Joy, G Hladik Clinical nephrology 62 (3), 193-201, 2004 | 136 | 2004 |
Determinants of vancomycin clearance by continuous venovenous hemofiltration and continuous venovenous hemodialysis MS Joy, GR Matzke, RF Frye, PM Palevsky American journal of kidney diseases 31 (6), 1019-1027, 1998 | 131 | 1998 |
Xenobiotic transporters and kidney injury B George, D You, MS Joy, LM Aleksunes Advanced drug delivery reviews 116, 73-91, 2017 | 125 | 2017 |
Comparative evaluation of the Cockcroft‐Gault Equation and the Modification of Diet in Renal Disease (MDRD) study equation for drug dosing: an opinion of the Nephrology … HA Nyman, TC Dowling, JQ Hudson, WLS Peter, MS Joy, TD Nolin Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 31 (11 …, 2011 | 125 | 2011 |
A primer on continuous renal replacement therapy for critically ill patients MS Joy, GR Matzke, DK Armstrong, MA Marx, BJ Zarowitz Annals of Pharmacotherapy 32 (3), 362-375, 1998 | 120 | 1998 |
Quantitative profiling of human renal UDP-glucuronosyltransferases and glucuronidation activity: a comparison of normal and tumoral kidney tissues G Margaillan, M Rouleau, JK Fallon, P Caron, L Villeneuve, V Turcotte, ... Drug Metabolism and Disposition 43 (4), 611-619, 2015 | 111 | 2015 |
Medication knowledge and compliance among patients receiving long-term dialysis DJ Cleary, GR Matzke, ACM Alexander, MS Joy American journal of health-system pharmacy 52 (17), 1895-1900, 1995 | 102 | 1995 |
Phase 1 trial of adalimumab in Focal Segmental Glomerulosclerosis (FSGS): II. Report of the FONT (Novel Therapies for Resistant FSGS) study group MS Joy, DS Gipson, L Powell, J MacHardy, JC Jennette, S Vento, C Pan, ... American Journal of Kidney Diseases 55 (1), 50-60, 2010 | 100 | 2010 |
Cytochrome P450 3A5 expression in the kidneys of patients with calcineurin inhibitor nephrotoxicity MS Joy, SL Hogan, BD Thompson, WF Finn, V Nickeleit Nephrology Dialysis Transplantation 22 (7), 1963-1968, 2007 | 96 | 2007 |
A long-term, open-label extension study on the safety of treatment with lanthanum carbonate, a new phosphate binder, in patients receiving hemodialysis WF Finn, MS Joy, LAM-308 Study Group Current medical research and opinion 21 (5), 657-664, 2005 | 74 | 2005 |
Complement activation in patients with focal segmental glomerulosclerosis JM Thurman, M Wong, B Renner, A Frazer-Abel, PC Giclas, MS Joy, ... PLoS One 10 (9), e0136558, 2015 | 71 | 2015 |
Calcineurin Inhibitor–Induced Nephrotoxicity and Renal Expression of P‐glycoprotein MS Joy, V Nickeleit, SL Hogan, BD Thompson, WF Finn Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 25 (6 …, 2005 | 71 | 2005 |
Association between thyroid disease and its treatment with ANCA small-vessel vasculitis: a case–control study S Lionaki, SL Hogan, RJ Falk, MS Joy, H Chin, CE Jennette, JC Jennette, ... Nephrology Dialysis Transplantation 22 (12), 3508-3515, 2007 | 69 | 2007 |
Cinacalcet HCl: a calcimimetic agent for the management of primary and secondary hyperparathyroidism N Franceschini, MS Joy, A Kshirsagar Expert opinion on investigational drugs 12 (8), 1413-1421, 2003 | 64 | 2003 |